Acknowledgements
ONCOLOGY
Financial support for this manuscript, including writing and editorial assistance by Laurie LaRusso, MS, ELS, and Carol Cadmus, ELS (Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA), was provided by Astellas Pharma, Inc. (Northbrook, IL, USA). The authors would like to thank Sebastian Attig and Richard Rae of TRON, Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH (Mainz, Germany) for performing the flow cytometry analyses. The authors would also like to thank Magdalena Utsch, Corinna Kloss, and Ulrich Luxemburger of Ganymed Pharmaceuticals AG for performing the ADCC assays.